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horizon model with 6-months of treatments every 5-years (3% discount rates for
cost and utilities), the projected incremental cost-effectiveness ratios (ICERS) for
3-5 flaresNo Tophi and6 flaresNo Tophi were $60,000K and $2,000K, respec-
tively. For the remaining gout states of RCG (3-5 flares  Tophi and 6 flares 
Tophi), pegloticase strictly dominates the placebo, producing better outcomes at
lower cost. Weighting these gout groups by their relative prevalence, the popula-
tion mean ICER shows pegloticase as dominant versus placebo. Given the initial
cost of therapy, the ICER varies depending on the timeframe: for: 3, 5, and 10-years,
the population ICERs are $68,000, $47,000, and $5,000, respectively. CONCLUSIONS:
Pegloticase is projected to be cost-effective compared to placebo treatment for
treating patients with RCG. The ICERs compare favorably with many technologies
in widespread use.
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OBJECTIVES: To identify which is the alternative that minimizes costs in the treat-
ment of Rheumatoid Arthritis with biological therapy in Mexico.METHODS: A cost
minimization evaluation was done, comparing alternatives considered compara-
ble in effectiveness in the management of RA in adult patients (Infliximab, Etaner-
cept and Adalimumab, Rituximab, Tocilizumab) in a 9-year horizon. Since the fre-
quency of retreatment with Rituximab hasn=t been standarized, the assumption of
the retreatment scheme of every 9 months as the average of the standards was
taken in account. Costs are expressed in US dollars. RESULTS: The total cost for 9
years with Rituximab was the lowest ($ 74,040), followed by Tocilizumab ($ 75,328),
Etanercept ($ 76,034), Adalimumab ($ 89,490) and Infliximab ($ 91,543), generating
savings with Rituximab of $ 1,288, $ 1,994, $ 15,450 and $ 17,503 respectively. Like-
wise, Rituximab was the alternative with the lowest number of applications (26),
compared with Tocilizumab (117), Etanercept (468), infliximab (60) and Adali-
mumab (234). In the budget impact analysis, assuming that 100%of the patients are
treated with Rituximab, the health facility could generate savings and therefore
could gain access to biological therapy to more patients tan if they were treated
under a scheme without Rituximab. The results of the sensitivity analysis, taking
as a variable number of applications of Rituximab year showed, with an 85.44% of
probability, that rituximab is shown to be the least costly alternative compared
with Infliximab; 74.09% compared with Adalimumab; 53.17% compared with Etan-
ercept, and with 51.38%, Rituximab is also less expensive compared to
Tocilizumab. CONCLUSIONS: Rituximab proved to be an alternative that mini-
mizes costs, generating savings and allowing greater access to therapy for patients
with RA, offering benefits to health institutions, not only improving the quality of
care with an innovative therapy, but also allowing significant cost savings.
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OBJECTIVES: To demonstrate the effect of ankylosing spondylitis (AS) on sick leave
and estimate the productivity loss due to the absenteeism. METHODS: Patients
diagnosed with AS who attended to tertiary-care outpatient rheumatology clinics
consecutivelywere evaluated for demographics, disease characteristics, treatment
regimens, WLQ, HAQ, BASDAI, and BASFI. Productivity loss, was calculated based
on the interim analysis results of this ongoing observational study. Data on total
days of sick leave in the last three months was used for the estimation of one-year
absenteeism. Additionally, the relationship between the sick leave and BASFI
scores was evaluated. RESULTS: Results from a total of 402 AS patients were ana-
lyzed. Among 220 patients (180 male (82 %); mean age 36.4 years; mean disease
duration 7.7 years) in paid employment, 56.4 % had sick leave over a period of 3
months and the mean duration of sick leave they reported on average was 8 days
(95% CI: 5.2-10.8). This duration was extrapolated to a total of 32 days per year.
Based on the national statistics, the average daily productivity loss for Turkey is
91.7 TL (calculated by dividing the average monthly productivity loss by 20). The
annual productivity loss was calculated as 2934.4 TL (1198 €) per patient due sick
leave caused byAS. Besides, 40.7%of these patientswho reported sick leave needed
to get support from their relatives or friends for their daily routine activities. The
mean BASFI score was 27.88 for patients who reported sick leave, while it was 22.3
for patients who did not and the difference is statistically significant.
CONCLUSIONS: Annual productivity loss due to sick leave caused by AS is 1198 €
per patient and there is a statistically significant difference between the BASFI
scores of those patients who had sick leave and those who did not.
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OBJECTIVES: This study reports dosing and refill compliance patterns observed in
golimumab (GLM) -treated rheumatoid arthritis (RA) patients.METHODS: A retro-
spective study was conducted of adult RA patients with 2 GLM prescriptions
between April 24, 2009 and December 31, 2010;  1 RA diagnosis during the study
period; continuous activity in the Source® LX database (6months pre;6months
post index prescription) and a 28-31 day GLM supply. Refill compliancewas defined
as occurring  1 week of the expected 28-31 day (d) interval. The percent of com-
pliant GLM refill intervals and the percent of patients with refill compliance at the
6th GLM dose were assessed. Descriptive statistics were used to characterize the
study population. RESULTS: A total of 1103 RA patients and 6432 GLM refill inter-
vals were observed. The sample was 82% female; mean age of 53 years with 63%
bio-experienced. A 50 mg GLM dose was found in 98% of all fills. Mean  SD refill
interval was 35.722.0 d; median was 31 d. Refill intervals were 35.421.3 d in
bio-experienced patients and 36.323.0 d in bio-naïve patients; medianwas 31 d in
both subgroups. Refill compliance was observed in 80% of all intervals. Refill com-
pliance at the 6th GLM dose was achieved by 84% of patients overall.
CONCLUSIONS: In this retrospective analysis of an administrative claims data-
base, 98% of GLM doses were 50 mg with approximately once monthly refill inter-
vals. Refill compliance was observed in 80% of all GLM refills and in greater than
80% of RA patients at the sixth GLM dose. Median refill interval and refill compli-
ance appeared similar in bio-experienced and bio-naïve subgroups. Further study
of these trends using additional data sources are desired to substantiate these
preliminary findings.
PMS39
LONG TERM MEDICATION ADHERENCE OF ADALIMUMAB AND ETANERCEPT
AMONG RHEUMATOID ARTHRITIS PATIENTS IN KAISER PERMANENTE
SOUTERN CALIFORNIA
Chu LH, Kawatakar AA
Kaiser Permanente Southern California, Pasadena, CA, USA
OBJECTIVES: The study objectives were to compare long term medication adher-
ence among first time adalimumab and etanercept users over a three-year follow
up period, and to identify factors that were associated with high medication
adherence.METHODS: A total of 1672 adult ( 18 years) rheumatoid arthritis (RA)
patients who were first time adalimumab (N382) or etanercept (N1290) users
between January 1, 2003 andDecember 31, 2007 in the Kaiser Permanente Southern
California (KPSC) Health Planwere included. Subjectswere required to have at least
two RA diagnosis records and disease-modifying anti-rheumatic drugs (DMARDs)
usewithin one year after the first diagnosis. Continuous enrollment one year prior,
and three years after the initiation (index date) of adalimumab and etanercept
treatment was required. First time users were defined as subjects who did not use
adalimumab or etanercept in the 12-month period prior to index date. Medication
adherence was measured through proportion days covered (PDC). Association of
long term high adherence with age, gender, race, insurance type, comorbidity and
history of oral DMARDs were estimated using Poisson regression with robust stan-
dard errors. RESULTS: The mean age, gender and race distribution were 52.5 years
old, 80.4% female, and 34.0% non-whites in adalimumab group; 53.3 years old,
77.9% female, and 36.2% non-whites in etanercept group. The adherence rate in
one-year, two-year and three-year follow up in adalimumab group was 0.63, 0.52
and 0.46, and in etanercept group was 0.69, 0.59 and 0.53. The incidence rate ratio
(IRR) of adalimumab was 0.78 (95% CI: 0.68 -0.90), 0.73 (95% CI: 0.61-0.88), and 0.70
(95% CI: 0.56-0.87) in one-year, two-year and three-year follow up respectively. Age
and history of oral DMARDs were significantly associated with adherence.
CONCLUSIONS: This study highlighted a relatively lower long term adherence rate
in adalimumab users as compared to etanercept users in adult RA patients within
KPSC.
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OBJECTIVES: Themain objective of this study was to assess themedication adher-
ence among individuals with rheumatoid arthritis (RA) enrolled in a stateMedicaid
fee-for-service (FFS) program. Factors influencing medication adherence were
identified. Lastly, the role of adherence in influencing the utilization of acute care
services (hospitalization/emergency room visit) was ascertained. METHODS: The
target population included nonelderly adult recipients (21-64 years) whowere con-
tinuously enrolled in the Mississippi Medicaid FFS program from January 1, 2006 to
December 31, 2007. Recipients who had a medical services claim with a primary or
secondary diagnosis of RA in calendar year 2006were identified. Medication adher-
ence (measured as proportion of days covered (PDC)) was determined using calen-
dar year 2007 data. Recipients with adherence (PDC) 80% were classified as ad-
herent. Logistic regression analyses were used to determine factors predicting
medication adherence and the effect of adherence on acute care services
utilization. RESULTS: Roughly 20% of recipients with RA were adherent. Older age
(odds ratio (OR) 1.031; p0.005), white race (OR 1.684; p0.005), and lower Charl-
son comorbidity index (CCI) score (OR 0.785; p0.005) were significant predictors
of adherence. Adherence did not have a significant association with acute care
services utilization after controlling for demographic and disease-related
covariates. CONCLUSIONS: Only one in five Medicaid recipients with RA were
found to be adherent. Lower levels of adherence among individuals with RA could
contribute to poor outcomes in these individuals over time. Policy makers should
undertake intervention programs aimed at increasing medication adherence in
this underprivileged population.
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